leadf
logo-loader
RNS
viewN4 Pharma PLC

N4 Pharma PLC - Placing to raise £2 million

RNS Number : 0543I
N4 Pharma PLC
09 December 2020
 

9 December 2020

 

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014 ("MAR").  In addition, market soundings (as defined in MAR) were taken in respect of the Placing with the result that certain persons became aware of inside information (as defined in MAR), as permitted by MAR.  This inside information is set out in this announcement.  Therefore, those persons that received inside information in a market sounding are no longer in possession of such inside information relating to the Company and its securities.

 

 

N4 Pharma plc

 

("N4 Pharma" or the "Company")

 

Placing to raise £2 million

 

 

N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, is pleased to announce that it has raised £2 million (before expenses) through a placing of 25,000,000 new ordinary shares of 0.4p each in the Company (the "Placing Shares") at an issue price of 8p per Placing Share (the "Placing").  The Placing, which was significantly oversubscribed, was undertaken by SP Angel Corporate Finance LLP.

 

The net proceeds of the Placing will be used for:

·    the extension of the formulation and current stability work covering DNA and mRNA formulations;

·    research on and evaluation of an additional asset to add to the Company portfolio;

·    business development driven by study results pending over next six months; and

·    ongoing working capital.

 

Nigel Theobald, Chief Executive of N4 Pharma, commented: "We are delighted with the positive response to our recent formulation work.  With vaccines and their delivery very much in the public consciousness we continue to grow our data package to present Nuvec® as a viable delivery technology solution to improve the delivery, storage and transportation of multiple existing and new vaccines.

 

"Whilst we are well funded for all existing work streams these additional funds will enable us to plan for follow on studies and more product focussed experiments as we move towards collaborations."  

 

Application for Admission

 

The Placing has been conducted utilising the Company's existing share authorities.  Application has been made for the Placing Shares to be admitted to trading on AIM ("Admission") and it is expected that Admission will take place and that trading will commence on AIM at 8.00 a.m. on or around 14 December 2020.  Once issued, the new Ordinary Shares will rank pari passu with the Company's existing ordinary shares. 

 

Total Voting Rights

 

Following Admission, the enlarged issued share capital of the Company will comprise 181,080,349 Ordinary Shares of 0.4 pence each.  The Company does not hold any ordinary shares in treasury.  Consequently, 181,080,349 is the figure which may be used by shareholders as the denominator for the calculation by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure and Transparency Rules.

 

 

Enquiries:

 

N4 Pharma plc


Nigel Theobald, CEO

Via IFC Advisory

Luke Cairns, Executive Director




SP Angel Corporate Finance LLP

Tel: +44(0)20 3470 0470

Nominated Adviser and Joint Broker


Matthew Johnson/Caroline Rowe (Corporate Finance)


Vadim Alexandre/Abigail Wayne/Rob Rees (Corporate Broking)




Turner Pope Investments (TPI) Limited

Tel: +44(0)20 3657 0050

Joint Broker


Andy Thacker




IFC Advisory Ltd

Tel: +44(0)20 3934 6630

Financial PR


Graham Herring


Zach Cohen 




 

About N4 Pharma

N4 Pharma is a specialist pharmaceutical company developing a novel delivery system for cancer and vaccine treatments using its unique silica nanoparticle delivery system called Nuvec®.

N4 Pharma's business model is to partner with companies developing novel antigens for cancer and vaccine treatments to use Nuvec® as the delivery vehicle to get their antigen into cells to express the protein needed for the required immunity.  As these products progress through pre clinical and clinical programs, N4 Pharma will seek to receive up front payments, milestone payments and ultimately royalty payments once products reach the market.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
IOETLBPTMTMMMPM

Quick facts: N4 Pharma PLC

Follow
AIM:N4P

Price: 7.8

Market Cap: £14.12 m

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

5 min read